Simvastatin: Review of Updates on Recent Trends in Pharmacokinetics, Pharmacodynamics, Drug–drug Interaction, Impurities and Analytical Methods

Author(s): Pawan Kumar Basniwal, Deepti Jain

Journal Name: Current Pharmaceutical Analysis

Volume 8 , Issue 2 , 2012

Become EABM
Become Reviewer
Call for Editor


Simvastatin, is a lipid regulating drug, which is a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase), obtained by synthesis from lovastatin. It is indicated in the treatment of hyperlipidemias, including hypercholesterolaemias, combined mixed hyperlipidemia hyperlipoproteinemias, hypertriglyceridemia, and primary dysbetalipoproteinemia. This review describes a brief overview of the chemistry including impurities and different synthetic schemes, pharmacokinetic, pharmacodynamic and adverse effect of simvastatin as well as the recent trends in drug–drug interaction studies of simvastatin with various drug categories such as antibacterials, anticoagulants, antidepressants, antifungals, antivirals, calcium-channel blockers, immunosuppressants, lipid regulating drugs and grapefruit juice. This review also focuses distinctly on comprehensive update of various analytical methods for the quantification of simvastatin and/or its metabolites, impurities, degradants and other drugs.

Keywords: Analytical methods, impurities, pharmacodynamics, pharmacokinetics and simvastatin, hypercholesterolaemias, immunosuppressants, degradants, antifungals, antidepressants

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 14 May, 2012
Page: [135 - 156]
Pages: 22
DOI: 10.2174/1573412911208020135
Price: $65

Article Metrics

PDF: 15